Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 18/20 | 1.00 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.65 |
| ▸ | FYN | P06241 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22047713 | 0.90 | HCAR3 (1.00) | HCAR3HCAR2FYN | |
| SCHEMBL11246840 | 0.88 | HCAR3 (0.97) | HCAR3HCAR2 | |
| Hydrochloric Acid SCHEMBL11180843 | 0.86 | HCAR3 (0.94) | HCAR3HCAR2 | |
| SCHEMBL186420 | 0.86 | HCAR3 (1.00) | HCAR3HCAR2MAPT | |
| SCHEMBL18193683 | 0.85 | HCAR3 (0.74) | HCAR3HCAR2 | |
| SCHEMBL7230169 | 0.85 | HCAR3 (0.73) | HCAR3HCAR2 | |
| SCHEMBL3562313 | 0.83 | HCAR3 (0.71) | HCAR3HCAR2 | |
| SCHEMBL31058294 | 0.83 | HCAR3 (0.71) | HCAR3HCAR2 | |
| SCHEMBL2128183 | 0.83 | HCAR3 (1.00) | HCAR3HCAR2 | |
| SCHEMBL13610833 | 0.83 | HCAR3 (0.70) | HCAR3HCAR2FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200055825-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas, Inc. | 2020-02-20 | — | — | US | disclosed |
| US-20130131075-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| EP-2401256-B1 | Compounds as bradykinin B1 antagonists | BOEHRINGER INGELHEIM INT (DE) | 2013-04-17 | — | — | EP | disclosed |
| EP-2401256-A1 | COMPOUNDS AS BRADYKININ B1 ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2012-01-04 | — | — | EP | disclosed |
| US-20100240669-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
| WO-2010097372-A1 | COMPOUNDS AS BRADYKININ B1 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055825-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, MDM2, ESRRA | HCAR3 467/4885HCAR2 447/4885FYN 2639/4885 |
| US-20130131075-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | HCAR3 302/4885HCAR2 1304/4885FYN 2615/4885 |
| US-20100240669-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | HCAR3 302/4885HCAR2 1304/4885FYN 2615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.